Pixie Dust Technologies (NASDAQ:PXDT) versus Soleno Therapeutics (NASDAQ:SLNO) Head-To-Head Review

Pixie Dust Technologies (NASDAQ:PXDT) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Valuation and Earnings

This table compares Pixie Dust Technologies and Soleno Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pixie Dust Technologies	$993.02 million	0.01	-$12.53 million	N/A	N/A
Soleno Therapeutics	N/A	N/A	-$38.99 million	($3.32)	-13.64

Pixie Dust Technologies has higher revenue and earnings than Soleno Therapeutics.

Profitability

This table compares Pixie Dust Technologies and Soleno Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pixie Dust Technologies	N/A	N/A	N/A
Soleno Therapeutics	N/A	-61.99%	-55.21%

Institutional and Insider Ownership

0.4% of Pixie Dust Technologies shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Pixie Dust Technologies has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.47, indicating that its stock price is 247% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Pixie Dust Technologies and Soleno Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pixie Dust Technologies	0	0	1	0	3.00
Soleno Therapeutics	0	0	6	1	3.14

Pixie Dust Technologies currently has a consensus price target of $5.21, suggesting a potential upside of 798.28%. Soleno Therapeutics has a consensus price target of $74.83, suggesting a potential upside of 65.19%. Given Pixie Dust Technologies’ higher probable upside, equities research analysts clearly believe Pixie Dust Technologies is more favorable than Soleno Therapeutics.

Summary

Pixie Dust Technologies beats Soleno Therapeutics on 6 of the 11 factors compared between the two stocks.

About Pixie Dust Technologies

Pixie Dust Technologies, Inc., a technology company, focuses on personal care and diversity, and workspace and digital transformation businesses primarily in Japan. It offers SonoRepro, an ultrasonic non-contact vibrotactile stimulation scalp care device; VUEVO, a series of directional voice arrival detection devices for individuals with deaf and hard-of-hearing; and kikippa, an acoustic stimulation device functioning as a desk-top speaker. The company also provides iwasemi, a sound-absorbing or sound-proofing material for architectural and interior design firms; hackke, a location positioning technology; KOTOWARI, a technology offering spatial analysis data; and magickiri, a planning services and monitoring service, which monitors human behavior and analyzes the customer's environment on the customer's behalf. In addition, it operates Pixie Nest, a membership forum, which hosts meetings and distributes information to facilitate solving social issues. The company was incorporated in 2017 and is headquartered in Tokyo, Japan.

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.